| First Author | Calvo-Rodriguez M | Year | 2024 |
| Journal | Mol Neurodegener | Volume | 19 |
| Issue | 1 | Pages | 6 |
| PubMed ID | 38238819 | Mgi Jnum | J:347907 |
| Mgi Id | MGI:7575145 | Doi | 10.1186/s13024-024-00702-2 |
| Citation | Calvo-Rodriguez M, et al. (2024) Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid beta aggregates in vivo in a mouse model of Alzheimer's disease. Mol Neurodegener 19(1):6 |
| abstractText | BACKGROUND: Reactive oxidative stress is a critical player in the amyloid beta (Abeta) toxicity that contributes to neurodegeneration in Alzheimer's disease (AD). Damaged mitochondria are one of the main sources of reactive oxygen species and accumulate in Abeta plaque-associated dystrophic neurites in the AD brain. Although Abeta causes neuronal mitochondria reactive oxidative stress in vitro, this has never been directly observed in vivo in the living mouse brain. Here, we tested for the first time whether Abeta plaques and soluble Abeta oligomers induce mitochondrial oxidative stress in surrounding neurons in vivo, and whether this neurotoxic effect can be abrogated using mitochondrial-targeted antioxidants. METHODS: We expressed a genetically encoded fluorescent ratiometric mitochondria-targeted reporter of oxidative stress in mouse models of the disease and performed intravital multiphoton microscopy of neuronal mitochondria and Abeta plaques. RESULTS: For the first time, we demonstrated by direct observation in the living mouse brain exacerbated mitochondrial oxidative stress in neurons after both Abeta plaque deposition and direct application of soluble oligomeric Abeta onto the brain, and determined the most likely pathological sequence of events leading to oxidative stress in vivo. Oxidative stress could be inhibited by both blocking calcium influx into mitochondria and treating with the mitochondria-targeted antioxidant SS31. Remarkably, the latter ameliorated plaque-associated dystrophic neurites without impacting Abeta plaque burden. CONCLUSIONS: Considering these results, combination of mitochondria-targeted compounds with other anti-amyloid beta or anti-tau therapies hold promise as neuroprotective drugs for the prevention and/or treatment of AD. |
